TLSI · NASDAQ · Medical - Devices

TriSalus Life Sciences (TLSI)

Sells PEDD infusion systems while developing nelitolimod for liver and pancreatic tumors.

$5.14
At close−0.03 (−0.58%)

Something off on this page? Send us feedback.

Next report
Nov 12, 2026
in 70 days
EPS estimate
−$0.12
Revenue estimate
$14.0M
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.35−$0.33−$0.27−$0.96−$0.12−$0.33−$0.16Pending
Estimate−$0.35−$0.20−$0.22−$0.17−$0.13−$0.16−$0.16−$0.12
Surprise0.0%−65.0%−22.7%−464.7%+7.7%−106.3%−3.2%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$8.3M$9.2M$11.2M$11.6M$13.2M$8.9M$11.4MPending
Estimate$8.1M$9.1M$11.7M$13.2M$12.8M$10.2M$10.3M$14.0M
Surprise+1.8%+0.8%−3.8%−12.4%+3.0%−12.7%+11.1%

History

DateEstimateReportedSurprise
Nov 2026−$0.12
Aug 2026−$0.16−$0.16−3.2%
May 2026−$0.16−$0.33−106.3%
Mar 2026−$0.13−$0.12+7.7%
Nov 2025−$0.17−$0.96−464.7%

The latest year is open to everyone — the 18 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Feb 2024
Nov 2023
Jun 2023
Mar 2023
Dec 2022
Nov 2022
Aug 2022
May 2022
Mar 2022
Dec 2021
Aug 2021
Jun 2021
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 12, 2026−$0.12$14.0M
Aug 6, 2026−$0.16−$0.16−3.2%$10.3M$11.4M+11.1%+15.2%
May 12, 2026−$0.16−$0.33−106.3%$10.2M$8.9M−12.7%−41.5%
Mar 5, 2026−$0.13−$0.12+7.7%$12.8M$13.2M+3.0%−6.3%
Nov 13, 2025−$0.17−$0.96−464.7%$13.2M$11.6M−12.4%+3.9%

The latest year is open to everyone — the 18 quarters behind it read with an account.

Sign in
Aug 12, 2025
May 15, 2025
Mar 27, 2025
Nov 14, 2024
Aug 14, 2024
May 15, 2024
Feb 27, 2024
Nov 14, 2023
Jun 30, 2023
Mar 31, 2023
Dec 31, 2022
Nov 10, 2022
Aug 10, 2022
May 11, 2022
Mar 2, 2022
Dec 13, 2021
Aug 16, 2021
Jun 28, 2021